3rd Quarter - Report

BROWN RUDNICK LLP for HOSPIRA, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues relating to drug shortages; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
LISA LAYMAN —
HENRY W MENN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Implementation of the Biologics Price Competition and Innovation Act (BPCIA) relating to biosimilar naming and reimbursement.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
LISA LAYMAN —
HENRY W MENN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.